Key result
Among 201,916 Australian patients on antihypertensive polytherapy in 2018, 1.4% were exposed to the inappropriate combination of ACE inhibitors and ARBs.
Why the study?
The study was conducted to estimate the prevalence of inappropriate antihypertensive polytherapy in Australia.
Population
Nationally representative 10% sample of PBS-eligible Australians aged 18+ years exposed to antihypertensives
Comparison
Inappropriate combinations, combinations to be used with caution, and fixed-dose vs free-drug combinations
Design
Nationally representative observational study using dispensing history
Authors
Loading...
Low ACEI-ARB co-prescription in Australian polytherapy may indicate guideline adherence; leaves open whether rates differ elsewhere or have changed since 2018.
Cross-Sectional (n=201,916)
Inappropriate antihypertensive polytherapy in Australia is low and decreasing, reflecting strong adherence to clinical guidelines, though vigilance is still needed for patients on 4 or more agents.
Falster et al. (2020) conducted a cross-sectional in Hypertension (Antihypertensive polytherapy) (n=201,916). Antihypertensive polytherapy was evaluated on Prevalence of inappropriate combinations (e.g., ACE inhibitors with ARBs). Among 201,916 Australian patients on antihypertensive polytherapy in 2018, 1.4% were exposed to the inappropriate combination of ACE inhibitors and ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: